Prostate Cancer Trial, Recruiting (NCT07468903)

Prostate Cancer Trial, Recruiting NCT07468903 Sponsor: Jonsson Comprehensive Cancer Center Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07468903 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma), confirmed by a tissue sample taken within the past 90 days
People whose prostate cancer has been identified on a specialised MRI scan (called a multiparametric MRI)
People whose cancer has not spread to other parts of the body or grown beyond the prostate, as confirmed by standard imaging tests (such as a bone scan, CT scan, MRI, or a PSMA PET scan)
People who are generally able to carry out normal daily activities, based on a standard medical assessment done within the past 60 days (confirm with trial site)
People aged 40 or older

Who may not be able to join:

People whose imaging scans show cancer has spread to lymph nodes or other parts of the body
People whose cancer affects more than 40% of the total prostate
People who have previously had radiation therapy to the pelvic area
People whose cancer has a higher-grade pattern (Gleason score above 6) in areas of the prostate outside the specific region being targeted for treatment (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07468903

Sponsor: Jonsson Comprehensive Cancer Center

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

More information: https://clinicaltrials.gov/study/NCT07468903

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma), confirmed by a tissue sample taken within the past 90 days
People whose prostate cancer has been identified on a specialised MRI scan (called a multiparametric MRI)
People whose cancer has not spread to other parts of the body or grown beyond the prostate, as confirmed by standard imaging tests (such as a bone scan, CT scan, MRI, or a PSMA PET scan)
People who are generally able to carry out normal daily activities, based on a standard medical assessment done within the past 60 days (confirm with trial site)
People aged 40 or older

Who may not be able to join:

People whose imaging scans show cancer has spread to lymph nodes or other parts of the body
People whose cancer affects more than 40% of the total prostate
People who have previously had radiation therapy to the pelvic area
People whose cancer has a higher-grade pattern (Gleason score above 6) in areas of the prostate outside the specific region being targeted for treatment (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Jonsson Comprehensive Cancer Center

Registry

ClinicalTrials.gov

Start date

11 May 2026

Est. completion

11 May 2031

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of grade 2 or greater genitourinary adverse events (AEs); Incidence of grade 2 or greater gastrointestinal AEs; Time to first grade 2 or greater adverse event; Local control rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov